Design Therapeutics, Inc. DSGN 深 沪
已收盘 02-06 16:00:00 美东时间
10.27
+0.320
+3.22%
华盛通- 最 高10.325
- 今 开10.20
- 成交量 24.68万股
- 最 低 9.93
- 昨 收 9.95
- 总市值 5.85亿
- 52周最高 10.97
- 市盈率 静 --
- 换手率 0.43%
- 52周最低 2.60
- 委 比 55.34%
- 总股本 5696.38万
- 历史最高 50.50
- 量 比 0.91
- 振 幅 3.97%
- 历史最低 1.94
- 每 手 1
- 风险率 2.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Oppenheimer Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $18
Oppenheimer analyst Trevor Allred initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Outperform rating and announces Price Target of $18.
01-07 20:36
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
2025-12-04 09:38
Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14
Leerink Partners analyst Joseph Schwartz upgrades Design Therapeutics (NASDAQ:DSGN) from Market Perform to Outperform and raises the price target from $7 to $14.
2025-12-03 21:41
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
2025-11-21 15:50
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones gaining more than 250 points on Thu...
2025-11-21 00:36
RBC Capital Upgrades Design Therapeutics to Outperform, Raises Price Target to $13
RBC Capital analyst Leonid Timashev upgrades Design Therapeutics (NASDAQ:DSGN) from Sector Perform to Outperform and raises the price target from $6 to $13.
2025-11-20 23:03
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
RBC Capital Maintains Sector Perform on Design Therapeutics, Raises Price Target to $6
RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Sector Perform and raises the price target from $5 to $6.
2025-11-06 23:48
Design Therapeutics Q3 EPS $(0.30) Beats $(0.34) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.34) by 11.76 percent. This is a 30.43 percent decrease over losses of $(0.23) per share
2025-11-06 06:27
